Nurix Therapeutics, Inc. $NRIX Stock Position Raised by Russell Investments Group Ltd.

Russell Investments Group Ltd. grew its holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report) by 171.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 504,041 shares of the company’s stock after buying an additional 318,517 shares during the period. Russell Investments Group Ltd.’s holdings in Nurix Therapeutics were worth $11,944,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. GAMMA Investing LLC raised its position in shares of Nurix Therapeutics by 95.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,270 shares of the company’s stock valued at $30,000 after purchasing an additional 620 shares during the last quarter. Nykredit A S acquired a new stake in Nurix Therapeutics in the 2nd quarter worth approximately $32,000. Integrated Wealth Concepts LLC purchased a new stake in Nurix Therapeutics during the 2nd quarter worth approximately $33,000. Fifth Third Bancorp grew its position in Nurix Therapeutics by 613.8% during the 3rd quarter. Fifth Third Bancorp now owns 1,556 shares of the company’s stock worth $37,000 after purchasing an additional 1,338 shares during the last quarter. Finally, KBC Group NV purchased a new stake in Nurix Therapeutics during the 1st quarter worth approximately $34,000.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on NRIX. HC Wainwright upped their price target on shares of Nurix Therapeutics from $34.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, October 16th. Morgan Stanley lifted their price objective on shares of Nurix Therapeutics from $36.00 to $38.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 28th. Wells Fargo & Company lowered their price objective on shares of Nurix Therapeutics from $25.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nurix Therapeutics in a report on Thursday, October 15th. Finally, Truist Financial dropped their price objective on shares of Nurix Therapeutics from $34.00 to $33.00 and set a “buy” rating on the stock in a report on Tuesday, October 13th. Fourteen analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $34.43.

Get Our Latest Stock Analysis on NRIX

Nurix Therapeutics Stock Performance

Shares of NRIX stock opened at $12.85 on Friday. The stock’s 50-day simple moving average is $22.07 and its 200-day simple moving average is $20.05. The firm has a market capitalization of $1.40 billion, a PE ratio of 5.56 and a beta of 1.80. Nurix Therapeutics, Inc. has a fifty-two week low of $12.82 and a fifty-two week high of $28.23.

Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) last announced its quarterly earnings data on Tuesday, October 13th. The company reported $4.73 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $5.33. Nurix Therapeutics had a return on equity of 49.34% and a net margin of 42.01%. The firm had revenue of $673.06 million during the quarter, compared to analysts’ expectations of $24.35 million. Sell-side analysts forecast that Nurix Therapeutics, Inc. will post 1.14 earnings per share for the current year.

Insider Activity at Nurix Therapeutics

In related news, Director Julia Gregory sold 22,583 shares of the stock in a transaction that occurred on Wednesday, October 14th. The shares were sold at an average price of $23.40, for a total value of $528,442.20. Following the transaction, the director owned 10,750 shares in the company, valued at approximately $251,550. This represents a 67.75% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Hans van Houte sold 4,769 shares of the stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $15.63, for a total transaction of $74,539.47. Following the completion of the transaction, the chief financial officer owned 42,745 shares in the company, valued at approximately $668,104.35. This trade represents a 10.04% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 38,499 shares of company stock worth $893,645 over the last quarter. Insiders own 6.70% of the company’s stock.

About Nurix Therapeutics

(Free Report)

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.

Recommended Stories

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIX – Free Report).

Institutional Ownership by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.